Illumina announced in San Diego, California, on November 9 an early-access program for a sequencing workflow designed to find very small amounts of tumor DNA in blood samples. The new duplex technology is for molecular residual disease research, not an approved diagnostic test, and the company expects early-access kits to ship in the first quarter of 2027 rather than immediately.
The company’s release, issued at 9:15 a.m. Eastern, says the workflow combines its NovaSeq X sequencing platform with DRAGEN analysis software. It is intended to support repeated whole-genome studies of molecular residual disease, or MRD: research into traces of disease-related genetic material that may remain during or after treatment. Finding a molecular signal is different from demonstrating that a test improves a patient’s treatment or survival.
The method examines both complementary strands of an original DNA molecule. Illumina says confirming a change on both strands helps distinguish a biological signal from errors introduced while preparing or sequencing a sample. The approach is designed to improve confidence when circulating tumor DNA, or ctDNA, makes up only a tiny fraction of the DNA in plasma.
In representative studies, the company says the workflow reproducibly detected ctDNA at 2.5 parts per million. It supports 5 to 10 nanograms of cell-free DNA input and reports sequencing quality scores above Q65. Those are company-reported analytical performance measures, not evidence that the workflow detects every cancer, predicts every recurrence or is ready for routine clinical diagnosis.
Illumina identifies NYU Langone Health as an early-access user applying the technology to MRD research. The release quotes Matija Snuderl, director of Molecular Pathology there, discussing plans to generate evidence with the approach. It does not disclose a completed NYU patient-outcomes study, clinical sensitivity and specificity across cancer types, or evidence that changing care on the basis of these results benefits patients.
The duplex workflow complements Illumina WGS Oncology Prep, another early-access product announced earlier this year for tumor fingerprinting and monitoring ctDNA over time. The new announcement therefore expands a research portfolio; it is not the first announcement of the earlier whole-genome workflow or proof that a diagnostic service has launched nationwide.
For laboratories, the proposed benefit is a standardized whole-genome process instead of building a custom panel for every sample. Illumina says its MRD research workflows run from library preparation through DRAGEN analysis in less than five days and are designed for implementation inside local laboratories. The release does not give independent comparisons of cost, turnaround time or performance in routine use.
For patients and clinicians, the importance is the research that may follow: better tools could help investigators study residual disease and tumor evolution, but the research-use-only designation limits what this announcement establishes. Kit shipment timing is a company expectation, and manufacturing, software reliability and adoption remain risks identified by Illumina. The release provides no kit price, broad commercial launch date, study cohort sizes or complete validation results. Those details, and evidence from clinical studies, are still needed before drawing conclusions about patient care.
JBizNews Desk | San Diego, California
© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.
